rivaroxaban
Blood and blood forming organs (B01)US regulatory status: approved. Molecular target: Coagulation factor X.
- Target
- Coagulation factor X
- Mechanism
- Coagulation factor X inhibitor
pharma · Acute Coronary Syndrome
Xiangya Hospital of
Second Xiangya Hospital of Central South University
Xiangya Hospital of drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Changsha, CN HQ
1906 Founded
316 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Changsha, CN
- Founded
- 1906
- Employees
- 316
- Programs
- 1
- Drugs
- 1
- Patents
- 0
Xiangya Hospital of pipeline
Portfolio lens on 1 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Xiangya Hospital of drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.